Drug Safety

, Volume 7, Issue 1, pp 32–45 | Cite as

Drug-Induced Gallbladder Disease

Incidence, Aetiology and Management
  • Peter P. Michielsen
  • Herbert Fierens
  • Yvan M. Van Maercke
Drug Experience


A great variety of drugs is reported to induce gallbladder disease by various pathogenetic mechanisms.

Early epidemiological studies indicated a doubled risk of gallbladder disease in women taking oral contraceptives. More recent studies, however, have failed to confirm those findings; these conflicting results might be explained by the different methods used to define gallbladder disease. It was shown that the lithogenic index of the bile is increased during intake of oral contraceptives. Estrogens cause hypersécrétion of cholesterol in bile, due to increase in lipoprotein uptake by the hepatocyte. Progesterone inhibits acyl coenzyme A-cholesterol acyl transferase (ACAT) activity, causing delayed conversion of cholesterol to cholesterol esters.

Of the lipid lowering drugs, only clofibrate has been shown to increase the risk for gallstone formation. The other fibric acid derivatives have similar properties, but clinical experience is not as extensive. They seem to be inhibitors of the ACAT enzyme system, thereby rendering bile more lithogenic.

Conflicting epidemiological data exist regarding the induction of acute cholecystitis by thiazide diuretics.

Ceftriaxone, a third-generation cephalosporin, is reported to induce biliary sludge in 25 to 45% of patients, an effect which is reversible after discontinuing the drug. The sludge is occasionally a clinical problem. It was clearly demonstrated that this sludge is caused by precipitation of the calcium salt of ceftriaxone excreted in the bile.

Long term use of octreotide is complicated by gallstone formation in approximately 50% of patients after 1 year of therapy, due to gallbladder stasis.

Hepatic artery infusion chemotherapy by implanted pump is shown to be associated with a very high risk of chemically induced cholecystitis. Prophylactic cholecystectomy at the time of pump implantation is therefore advocated.

Some drugs, such as erythromcyin or ampicillin, are reported to cause hypersensitivityinduced cholecystitis.

Furthermore, there are reports on the influence of cyclosporin, dapsone, anticoagulant treatment, and narcotic and anticholinergic medication in causing gallbladder disease.


Octreotide Ceftriaxone Acromegaly Cholecystitis Acute Cholecystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahrendt SA, McGuire GE, Pitt HA, Lillemoe KD. Why does somatostatin cause gallstones? American Journal of Surgery 161: 177–183, 1991PubMedCrossRefGoogle Scholar
  2. Alemayehu G, Näslund I. Erytromycin orsakade leverskada och gallblaseinflammation. Läkartidningen 87: 2866, 1990PubMedGoogle Scholar
  3. Anderson A, James OFW, MacDonald HA, Snowball S, Taylor W. The effect of ethynyl oesiradiol on biliary lipid composition in young men. European Journal of Clinical Investigation 10: 77–80, 1980PubMedCrossRefGoogle Scholar
  4. Barbara L, Sama C, Morselli Labate AM, Taroni F, Rusticali AG, et al. A population study on the prevalence of gallstone disease: the Sirmione study. Hepatology 5: 913–915, 1987CrossRefGoogle Scholar
  5. Bennion LJ, Ginsberg RL, Garnick MB, Bennett PH. Effects of oral contraceptives on the gallbladder bile of normal women. New England Journal of Medicine 294: 189–192, 1976PubMedCrossRefGoogle Scholar
  6. Bennion LJ, Mott DN, Howard BV. Oral contraceptives raise the cholesterol saturation of the bile by increasing biliary secretion. Metabolism 29: 18–22, 1980PubMedCrossRefGoogle Scholar
  7. Berk JE. Management of acute cholecystitis. American Journal of Digestive Diseases 7: 325–332, 1940CrossRefGoogle Scholar
  8. Boden G, Shimoyama R. Somatostatinoma. In Cohen & Soloway (Eds) Hormone-producing tumors of the gastrointestinal tract, pp. 85–99, Churchill-Livingstone, New York, 1985Google Scholar
  9. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet 2: 1399–1404, 1973Google Scholar
  10. Boston Collaborati/e Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. New England Journal of Medicine 290: 15–19, 1974CrossRefGoogle Scholar
  11. Buscail I, Tauber JP, Puel-Bosquet C, Escourrou J, Bayard F, et al. Gall stones and treatment with octreotide for acromegaly. British Medical Journal 299: 1162, 1989Google Scholar
  12. Braverman DZ, Johnson ML, Kern F. Effects of pregnancy and contraceptive steroids on gallbladder function. New England Journal of Medicine 302: 362–364, 1980PubMedCrossRefGoogle Scholar
  13. Cahalane MJ, Neubrand MW, Carey MC. Physical-chemical pathogenesis of pigment gallstones. Seminars in Liver Disease 8: 317–328, 1988PubMedCrossRefGoogle Scholar
  14. Carey MC. Formation of cholesterol gallstones: the new paradigms. In Paumgartner et al. (Eds) Trends in biie acid research, pp. 258–281, Kluwer, Dordrecht, 1989Google Scholar
  15. Carey MC. Overview of the pathogenetic events in biliary stone formation. In Tytgat & van Blankenstein (Eds) Current topics in gastroenterology and hepatology, pp. 394–402, Georg Thieme verlag, Stuttgart -New York, 1990Google Scholar
  16. Carey MC, Cahalane MJ. Whither biliary sludge? Gastroenterology 95: 508–523, 1988PubMedGoogle Scholar
  17. Carey MC, O’Donovan MA. Gallstone disease: current concepts on the epidemiology, pathogenesis and management. In Petersdorf et al. (Eds) Harrison’s principles of internal medicine, update V, pp. 139–168, McGraw-Hill, New York, 1984Google Scholar
  18. Carrasco CH, Freeny PC, Chuang VP, Wallace S. Chemical cholecystitis associated with hepatic artery infusion chemotherapy. American Journal of Radiology 141: 703–706, 1983Google Scholar
  19. Case Records of the Massachusetts General Hospital. Case 12-1973. New England Journal of Medicine 288: 620–626, 1973Google Scholar
  20. Choy AM, Lang CC. Gall-bladder perforation after long-term dapsone therapy. Journal of Internal Medicine 228: 409–410, 1990PubMedCrossRefGoogle Scholar
  21. Chung-Park M, Kim B, Mrmolya G, Karlins N, Wojcik E. Acalculous lymphoeosinophilic cholecystitis associated with inter-leukin-2 and lymphokine-activated killer cell therapy. Archives of Pathology and Laboratory Medicine 114: 1073–1075, 1990PubMedGoogle Scholar
  22. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. British Heart Journal 40: 1069–1118, 1978CrossRefGoogle Scholar
  23. Cooper J, Geizerova H, Olivier MF. Clofibrate and gallstones. Lancet 1: 1083, 1975PubMedCrossRefGoogle Scholar
  24. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. Journal of the American Medical Association 231: 360–381, 1975CrossRefGoogle Scholar
  25. Coronary Drug Project Research group. Gallbladder disease as a side effect of drugs influencing lipid metabolism. New England Journal of Medicine 296: 1185–1190, 1977CrossRefGoogle Scholar
  26. Dao TH, Rotman N, Mathieu D Vasile N. Hématome infiltrant du pédicule hépatique et de la paroi vésiculaire: aspect échographique et tomodensitométrique. Journal de Radiologie 70: 431–433, 1989PubMedGoogle Scholar
  27. DeCamp PT, Ochsner A, Baffes TG, Bancroft H, Bendel W. Timing in the surgical treatment of acute cholecystitis. Annals of Surgery 135: 734–750, 1952CrossRefGoogle Scholar
  28. Down RHL, Whiting MJ, Watts JMcK, Jones W. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition. Gut 24: 253–259, 1983PubMedCrossRefGoogle Scholar
  29. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, et al. Simvastatin, a competitive inhibitor of HMG CoA reductase lowers cholesterol saturation index of gallbladder bile. Hepatology 8: 1147–1150, 1988PubMedCrossRefGoogle Scholar
  30. Ensminger WD, Niederhuber JE, Dakhil S, Thrall J, Wheeler R. A totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treatment Reports 65: 393–400, 1981PubMedGoogle Scholar
  31. Erickson SK, Cooper AD. Acyl-coenzyme A: cholesterol acyltransferase in human liver: in vitro detection and some characteristics of the enzyme. Metabolism 29: 991–996, 1980PubMedCrossRefGoogle Scholar
  32. Eriksson M, Berglund L, Ruding M, Hendriksson P, Angelin B. Effects of estrogen on low density lipoprotein metabolism in males: short-term and long-term studies during hormonal treatment of prostatic carcinoma. Journal of Clinical Investigation 84: 802–810, 1989PubMedCrossRefGoogle Scholar
  33. Everson RB, Byar DP, Bischoff AJ. Estrogen predisposes to cholecystectomy but not to stones. Gastroenterology 82: 4–8, 1982PubMedGoogle Scholar
  34. Fisher RS, Rock E, Levin G, Malmud L. Effects of somatostatin on gallbladder emptying. Gastroenterology 92: 885–890, 1987PubMedGoogle Scholar
  35. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317: 1237–1245, 1987PubMedCrossRefGoogle Scholar
  36. Glenn F. Acute acalculous cholecystitis. Annals of Surgery 189: 458–465, 1979PubMedGoogle Scholar
  37. Glenn F, Becker CG. Acute acalculous cholecystitis: an increasing entity. Annals of Surgery 195: 131–136, 1982PubMedCrossRefGoogle Scholar
  38. Glenn TA. A 26 year experience in the surgical treatment of 5,037 patients with nonmalignant biliary tract disease. Surgery, Gynecology and Obstetrics 102: 145–152, 1956PubMedGoogle Scholar
  39. Goldberg R, La Belle P, Zupkis R, Ronca Ph. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. American Journal of Cardiology 66: 16B-21B, 1990CrossRefGoogle Scholar
  40. Gracie WA, Ransohoff DF. The natural history of silent gallstones: the innocent gallstone is not a myth. New England Journal of Medicine 307: 798–800, 1982PubMedCrossRefGoogle Scholar
  41. Grundy SM, Ahrens Jr EH, Sälen G, Schreibman PH, Nestel PL Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. Journal of Lipid Research 13: 531–551, 1972PubMedGoogle Scholar
  42. Hartmann G, Micheli H, Mordasini R, Noseda G, Stähelin HB. Editorial. Clofibrat — Nutzen oder Schaden? Schweizerische Medizinische Wochenschrift 109: 1137–1139, 1979Google Scholar
  43. Hay DW, Carey MC. Pathophysiology and pathogenesis of cholesterol gallstone formation. Seminars in Liver Disease 10: 159–170, 1990PubMedCrossRefGoogle Scholar
  44. Hendriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. Journal of Clinical Investigation 84: 811–816, 1989CrossRefGoogle Scholar
  45. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201–995 (octreotide) in acromegaly. Annals of Internal Medicine 112: 173–181, 1990PubMedGoogle Scholar
  46. Hoogerbrugge-vd Linden N, de Rooy FWM, Jansen H, van Blankenstein M. Effects of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolemia. Gut 31: 348–350, 1990PubMedCrossRefGoogle Scholar
  47. Housholder DF, Hynes HE, Dakhil SR, Marymont JV. Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy. Journal of Nuclear Medicine 26: 474–477, 1985PubMedGoogle Scholar
  48. Howard RJ. Acute acalculous cholecystitis. American Journal of Surgery 141: 194–198, 1981PubMedCrossRefGoogle Scholar
  49. Hunninghake DB. Clinical trials of lovastatin and simvastatin versus cholestyramine. Atherosclerosis Reviews 18: 133–138, 1988Google Scholar
  50. Jacobs RF. Ceftriaxone-associated cholecystitis. Pédiatrie Infectious Disease Journal 7: 434–436, 1988CrossRefGoogle Scholar
  51. Jorgensen T. Prevalence of gallstones in a Danish population. American Journal of Epidemiology 126: 912–921, 1987PubMedGoogle Scholar
  52. Jørgensen T. Gall stones in a Danish population: fertility period, pregnancies, and exogenous female sex hormones. Gut 29: 433–439, 1988PubMedCrossRefGoogle Scholar
  53. Judd ES, Phillips JR. Acute cholecystitic disease. Annals of Surgery 98: 771–779, 1933PubMedCrossRefGoogle Scholar
  54. Jutrus JA, Longtin JM, Levesque HP. Hyperplastic cholecystoses. American Journal of Roentgenology 83: 795–827, 1960Google Scholar
  55. Keane PF, Clanachan AS, Scott GW. Influence of age, gender, and progesterone on gallbladder motility in vitro. Surgical Forum 35: 467–468, 1984Google Scholar
  56. Kern Jr F, Everson GT. Contraceptive steroids increase cholesterol in bile: mechanisms of action. Journal of Lipid Research 28: 828–839, 1987PubMedGoogle Scholar
  57. Kern Jr F, Everson GT, Demark B, McKinley C, Showalter R, et al. Biliary lipids, bile acids, and gallbladder function in the human female: effects of contraceptive steroids. Journal of Laboratory and Clinical Medicine 99: 798–805, 1982PubMedGoogle Scholar
  58. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Medical Toxicology 2: 10–32, 1987PubMedGoogle Scholar
  59. Lafon PC, Reed K, Rosenthal D. Acute cholecystitis associated with hepatic arterial infusion of floxuridine. American Journal of Surgery 150: 687–689, 1985PubMedCrossRefGoogle Scholar
  60. Layde PM, Vessey MP, Yeates D. Risk factors for gall-bladder disease: a cohort study of young women attending family planning clinics. Journal of Epidemiology and Community Health 36: 274–278, 1982PubMedCrossRefGoogle Scholar
  61. Leiss O, Bergmann von K, Gnasso A, Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism 34: 74–82, 1985PubMedCrossRefGoogle Scholar
  62. Leissner K-H, Wedel H, Scherstén T. Comparison between the use of oral contraceptives and the incidence of surgically confirmed gallstone disease. Scandinavian Journal of Gastroenterology 12: 893–986, 1977PubMedCrossRefGoogle Scholar
  63. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, et al. Effect of the somatostatin analogue sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36: 108–124, 1987PubMedCrossRefGoogle Scholar
  64. Lichtenstein AH, Brecher P. Properteries of acyl-CoA: cholesterol acyltransferase in rat liver microsomes. Journal of Biological Chemistry 255: 9098–9104, 1980PubMedGoogle Scholar
  65. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 251: 351–364, 1984CrossRefGoogle Scholar
  66. Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 43: 35–40, 1987PubMedCrossRefGoogle Scholar
  67. Magnusson I, Einarsson K, Angelin B, Nyberg B, Bergstrom K, et al. Effects of somatostatin on hepatic bile formation. Gastroenterology 96: 206–212, 1989PubMedGoogle Scholar
  68. Malet PF, Dabezies MA, Huang G, Long WB, Gadacz TR, et al. Quantitative infrared spectroscopy of common bile duct gallstones. Gastroenterology 94: 1217–1221, 1988PubMedGoogle Scholar
  69. Mandelbaum I, Palmer RM. Post-traumatic acalculous cholecystitis. Archives of Surgery 97: 601–604, 1968PubMedCrossRefGoogle Scholar
  70. Marteau P, Chrétin Y, Calmus Y, Parc R, Poupon R. Pharmacological effects of somatostatin on bile secretion in man. Digestion 42: 16–21, 1989PubMedCrossRefGoogle Scholar
  71. Marymont JV, Dakhil SR, Travers H, Housholder DF. Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. Human Pathology 16: 986–990, 1985PubMedCrossRefGoogle Scholar
  72. McKnight JA, McCance DR, Crothers JG, Atkinson AB. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. British Medical Journal 299: 604–605, 1989PubMedCrossRefGoogle Scholar
  73. Meyboom RHB, Kuiper H, Jansen A. Ceftriaxone and reversible cholelithiasis. British Medical Journal 297: 858, 1988PubMedCrossRefGoogle Scholar
  74. Michels NA. Blood supply and anatomy of the upper abdominal organs, J.B. Lippincott, Philadelphia, 1955Google Scholar
  75. Michielsen P, Pelckmans P, Van Maercke Y. Oral cholecystography or ultrasonography in the diagnosis of calculous gallbladder disease. Acta Gastroenterologica Belgica 51: 215–222, 1988Google Scholar
  76. Nervi FO, Del Pozo R, Covarrubias CF, Ronco BO. The effect of progesterone on the regulatory mechanisms of biliary cholesterol secretion in the rat. Hepatology 3: 360–367, 1983PubMedCrossRefGoogle Scholar
  77. Niederhuber JE, Ensminger WD. Surgical considerations in the management of hepatic neoplasia. Seminars in Oncology 10: 135–147, 1983PubMedGoogle Scholar
  78. Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336–1343, 1984PubMedCrossRefGoogle Scholar
  79. O’Fallon WM, Labarthe DR, Kurland LT. Rauwolfia derivatives and breast cancer. Lancet 2: 292–296, 1975PubMedCrossRefGoogle Scholar
  80. Orlando III R, Gleason E, Drezner AD. Acute acalculous cholecystitis in the critically ill patient. American Journal of Surgery 145: 472–476, 1983PubMedCrossRefGoogle Scholar
  81. Ottery FD, Scupham RK, Weese JL. Chemical cholecystitis after intrahepatic chemotherapy: the case for prophylactic cholecystectomy during pump placement. Diseases of the Colon and Rectum 29: 187–190, 1986PubMedCrossRefGoogle Scholar
  82. Page MD, Millward ME, Taylor A, Preece M, Hourihan M, et al. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide. Quarterly Journal of Medicine 74: 189–201, 1990PubMedGoogle Scholar
  83. Palmer RH. Prevalance of gallstones in hyperlipidemics and incidence during treatment with clofibrate and/or cholestyramine. Transactions of the Association of American Physicians 91: 424–428, 1978PubMedGoogle Scholar
  84. Palmer RH. Ceftriaxone-associated gallbladder sludge: what’s in a name? Gastroenterology 100: 1769–1772, 1991PubMedGoogle Scholar
  85. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge: identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 100: 1665–1670, 1991PubMedGoogle Scholar
  86. Parry SW, Pelias ME, Browder W. Acalculous hypersensitivity cholecystitis: hypothesis of a new clinicopathologic entity. Surgery 104: 911–916, 1988PubMedGoogle Scholar
  87. Pertsemlidis D, Panveliwalla D, Ahrens EH. Effect of clofibrate and of oral contraceptives on biliary lipid composition and bile acid kinetics in man. Gastroenterology 66: 565–573, 1974PubMedGoogle Scholar
  88. Pertsemlidis D, Panveliwalla D, Kimball A. Effects of clofibrate and of oral contraceptives on biliary lipid composition and bile acid kinetics in man. Abstract A99. Gastroenterology 64: 782, 1973Google Scholar
  89. Pietrafitta JJ, Anderson BG, O’Brien MJ, Deckers PJ. Cholecystitis secondary to infusion chemotherapy. Journal of Surgical Oncology 31: 287–293, 1986PubMedCrossRefGoogle Scholar
  90. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet 2: 165, 1989PubMedCrossRefGoogle Scholar
  91. Plöckinger U, Dienemann D, Quabbe H-J. Gastrointestinal side-effects of octreotide during long term treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 71: 1658–1662, 1990PubMedCrossRefGoogle Scholar
  92. Porter JB, Jick H, Dinan BJ. Acute cholecystitis and thiazides. New England Journal of Medicine 304: 954–955, 1981PubMedCrossRefGoogle Scholar
  93. Robertson RD. Noncalculous acute cholecystitis following surgery, trauma and illness. American Surgeon 36: 610–614, 1970PubMedGoogle Scholar
  94. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO). Prevalence of gallstone disease in an Italian adult female population. American Journal of Epidemiology 119: 796–805, 1984Google Scholar
  95. Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO). The epidemiology of gallstone disease in Rome, Italy. Part 1. Prevalence data in men. Part II. The epidemiology of gallstone disease in Rome, Italy. Hepatology 8: 904–913, 1988CrossRefGoogle Scholar
  96. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, et al. Thiazides and acute cholecystitis. New England Journal of Medicine 303: 546–548, 1980PubMedCrossRefGoogle Scholar
  97. Roslyn JJ, Pitt HA, Mann LL, Ament ME, DenBesten L. Gallbladder disease in patients on long-term parenteral nutrition. Gastroenterology 84: 148–154, 1983PubMedGoogle Scholar
  98. Royal College of General Practitioners’ Oral Contraception Study. Oral contraceptives and gallbladder disease. Lancet 2: 957–959, 1982Google Scholar
  99. Sama C, Morselli Labate M, Taroni F, Barbara L. Epidemiology and natural history of gallstone disease. Seminars in Liver Disease 10: 149–158, 1990PubMedCrossRefGoogle Scholar
  100. Schaad UB, Suter S, Gianelli-Borradori A, Pfenninger J, Auckenthaler R, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. New England Journal of Medicine 322: 141–147, 1990PubMedCrossRefGoogle Scholar
  101. Schaad UB, Tschaeppeler H, Lentaz MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pédiatric Infectious Disease Journal 5: 708–710, 1986CrossRefGoogle Scholar
  102. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 2: 1411–1413, 1988PubMedCrossRefGoogle Scholar
  103. Schiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge: in vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 99: 1772–1778, 1990Google Scholar
  104. Scragg RKR, McMichael AJ, Seamark RF. Oral contraceptives, pregnancy, and endogenous oestrogen in gall stone disease -a case-control study. British Medical Journal 288: 1795–1799, 1984PubMedCrossRefGoogle Scholar
  105. Spes CH, Angermann CE, Beyer RW, Schreiner J, Lehnert P, et al. Increased incidence of cholelithiasis in heart transplant recipients receiving cyclosporin therapy. Journal of Heart Transplantation 9: 404–407, 1990PubMedGoogle Scholar
  106. Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Safety 6: 118–130, 1991PubMedCrossRefGoogle Scholar
  107. Stolley PD, Tonascia JA, Fockman MS, Sartwell PE, Rutledge AH, et al. Thrombosis with low-estrogen oral contraceptives. American Journal of Epidemiology 102: 197–208, 1975PubMedGoogle Scholar
  108. Teelmann K, Scharer K, Udaka K. Experimentelle Toxikologie von Ceftriaxone (Ro 13-9904, Rocephin®): Ceftriaxone ein neues parenterales Cephalosporin. In Grieshaber (Ed.) Proceedings of the Hahnenklee-Symposium, September 1981, pp. 91–111, Editiones Roche, Basel, 1982Google Scholar
  109. Van der Linden W, Ritter B, Edlund G. Acute cholecystitis and thiazides. British Medical Journal 289: 654–655, 1984PubMedCrossRefGoogle Scholar
  110. Wass JAH, Anderson JV, Besser GM. Gall stones and treatment with octreotide for acromegaly. British Medical Journal 299: 1162–1163, 1989CrossRefGoogle Scholar
  111. Watts J.McK, Dunphy JE. The role of the common bile duct in biliary dynamics. Surgery, Gynecology and Obstetrics 122: 1207–1218, 1966PubMedGoogle Scholar
  112. Weedon D. Diseases of the gallbladder. In MacSween et al. (Eds) Pathology of the liver, pp. 454–477, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1987Google Scholar
  113. White CM, Howat JMT, Shofield PF. Lithogenic bile: a study in women taking oral contraceptives. British Journal of Surgery 63: 664, 1976PubMedGoogle Scholar
  114. Xia Y, Lambert KJ, Schteingart CD, Gu JJ, Hofmann AF. Concentrative biliary excretion of ceftriaxone: inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 99: 454–465, 1990PubMedGoogle Scholar
  115. Yeung E, Jackson J, Fin JP, Thomas MG, Benjamin IS, et al. Acalculous cholecystitis complicating hepatic intraarterial lipiodol: case report. Cardiovascular and Interventional Radiology 12: 80–82, 1989PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Peter P. Michielsen
    • 1
  • Herbert Fierens
    • 1
  • Yvan M. Van Maercke
    • 1
  1. 1.Division of GastroenterologyUniversity Hospital of AntwerpEdegemBelgium

Personalised recommendations